Paper published in a journal (Scientific congresses and symposiums)
Long term follow-up of liver transplant recipients after allogeneic mesenchymal stromal cell infusion
VANDERMEULEN, Morgan; Mohamed Wais, M; DELBOUILLE, Marie-Hélène et al.
2021In Transplant International, 34 (S1 OP282), p. 45
Peer Reviewed verified by ORBi
 

Files


Full Text
OP282.pdf
Publisher postprint (136.77 kB)
Download

All documents in ORBi are protected by a user license.

Send to



Details



Abstract :
[en] Background: Some properties of mesenchymal stromal cells (MSCs) might be particularly of interest after organ transplantation. The authors aimed to report herein the long-term results of their first-in man, prospective, controlled, phase-1 study evaluating the safety of a single third-party MSC infusion after liver transplantation (LT). Methods: Ten liver transplant recipients under standard immunosuppression received 1.5–3 9 106/kg unrelated third-party MSCs on post-operative day 3 ! 2 and were prospectively compared to a control group of 10 liver transplant recipients. Primary endpoints were set to prospectively detect potential delayed side effects of MSC infusion, and particularly occurrence of infections and cancers. As secondary endpoints, liver graft- and patient survivals, graft rejection and function, occurrence of bile duct complications, and development of anti-HLA antibodies against liver- or MSC-donors were studied. Results: There was no difference in overall rates of infection or cancer at 5 years of follow-up between the two groups. There was also no difference in liver graft- and patient survivals, graft rejection, blood liver tests or occurrence of bile duct complications. The prevalence of de novo liver DSA related to HLA-mismatches was two times higher in the MSC group compared to the control group. Three patients of the MSC group (30%) developed at least 1 de novo HLA antibody against MSC-donor. All the de novo class II HLA antibodies against MSC were linked to a shared HLA mismatch between the liver and MSC donors and 75% of HLA class II shared-mismatches led to de novo HLA antibodies. Conclusions: This long-term follow-up confirms the safety of one single MSC infusion after LT. The potential interesting effects of MSC need to be confirmed by prospective studies. The development of anti-HLA antibodies against MSC donor should be further evaluated especially in case of shared HLAmismatchesbetween graft- and MSC-donors, despite the fact that no deleterious effect could be detected.
Disciplines :
Surgery
Gastroenterology & hepatology
Author, co-author :
VANDERMEULEN, Morgan ;  Centre Hospitalier Universitaire de Liège - CHU > Département de chirurgie > Chirurgie abdo, sénologique, endocrine et de transplantation
Mohamed Wais, M
DELBOUILLE, Marie-Hélène ;  Centre Hospitalier Universitaire de Liège - CHU > Département de chirurgie > Chirurgie abdo, sénologique, endocrine et de transplantation
MAGGIPINTO, Gianni ;  Centre Hospitalier Universitaire de Liège - CHU > Unilab > Laboratoire immunologie de la transplantation
BEGUIN, Yves  ;  Centre Hospitalier Universitaire de Liège - CHU > Département de médecine interne > Service d'hématologie clinique
DETRY, Olivier  ;  Centre Hospitalier Universitaire de Liège - CHU > Département de chirurgie > Chirurgie abdo, sénologique, endocrine et de transplantation
Language :
English
Title :
Long term follow-up of liver transplant recipients after allogeneic mesenchymal stromal cell infusion
Publication date :
August 2021
Event name :
ESOT 2021
Event organizer :
European Society of Transplantation
Event place :
Milan, Italy
Event date :
Du 29 aout au 1 septembre 2021
Audience :
International
Journal title :
Transplant International
ISSN :
0934-0874
eISSN :
1432-2277
Publisher :
Blackwell, Oxford, United Kingdom
Volume :
34
Issue :
S1 OP282
Pages :
45
Peer reviewed :
Peer Reviewed verified by ORBi
Available on ORBi :
since 30 August 2021

Statistics


Number of views
153 (14 by ULiège)
Number of downloads
120 (9 by ULiège)

Bibliography


Similar publications



Contact ORBi